-
公开(公告)号：US20140220033A1
公开(公告)日：2014-08-07
申请号：US14171670
申请日：2014-02-03
Applicant: Santa Maria Biotherapeutics, Inc. , Amgen Inc.
Inventor： Huiquan Han , Isaac Ciechanover , Christopher Michael Haqq , Xiaolan Zhou , John Zhao-Nian Lu
IPC: C07K16/22 , A61K39/395 , A61K31/7068 , A61K47/48 , A61K45/06
CPC classification number: C07K16/22 , A61K31/704 , A61K31/7068 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/21 , C07K2317/73 , A61K2300/00
Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment by evaluating the subject's expression levels of specific biomarkers or angiogenic factors.
Abstract translation: 本发明涉及通过向受试者施用抗激活素-A化合物，例如抗激活素-A抗体或激活素-A结合受体来治疗受试者的卵巢癌的方法。 在一些实施方案中，向受试者施用至少两种化合物，其中第一种化合物是抗激活素A化合物，而第二种化合物是化疗化合物，例如卡培他滨。 本发明还涉及通过评估受试者的特异性生物标志物或血管生成因子的表达水平来鉴定受试者的方法。
-
Patent Agency Ranking
公开(公告)号：US20150359850A1
公开(公告)日：2015-12-17
申请号：US14764288
申请日：2014-02-03
Applicant: SANTA MARIA BIOTHERAPEUTICS, INC. , AMGEN INC.
Inventor： Huiquan Han , Christopher Michael Haqq , Isaac Ciechanover , Xiaolan Zhou , John Zhao-Nian Lu
IPC: A61K38/17 , A61K31/704 , C07K16/22 , A61K31/7068 , A61K45/06 , A61K39/395
CPC classification number: A61K31/704 , A61K31/7068 , A61K38/177 , A61K38/1796 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/22 , C07K2317/76 , A61K2300/00
Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
Abstract translation: 本发明涉及通过对受试者施用特异性生物标志物或血管生成的抗激活素-A化合物（例如抗激活素-A抗体或激活素-A抗体）的受试者的表达水平，对受试者施用治疗卵巢癌的方法。 A结合受体。 在一些实施方案中，向受试者施用至少两种化合物，其中第一种化合物是抗激活素A化合物，而第二种化合物是化疗化合物，例如卡培他滨。 本发明还涉及鉴定治疗因素的受试者的方法。
-
公开(公告)号：US20240277805A1
公开(公告)日：2024-08-22
申请号：US18224463
申请日：2023-07-20
Applicant: Santa Maria Biotherapeutics, Inc. , AMGEN INC.
Inventor： Christopher Michael HAQQ , Ramil LATYPOV
CPC classification number: A61K38/179 , C07K14/71
Abstract: Disclosed herein is an activin receptor IIB-based composition and related methods of use, e.g., to treat solid tumors. Also disclosed are methods of manufacturing the compound and formulation.
-
公开(公告)号：US20160333418A1
公开(公告)日：2016-11-17
申请号：US15111034
申请日：2015-01-14
Applicant: SANTA MARIA BIOTHERAPEUTICS, INC.
Inventor： Christopher Michael Haqq
CPC classification number: C12Q1/6886 , A61K38/179 , C12Q2600/106 , C12Q2600/158
Abstract: Described herein are methods and assays for determining the presence or absence of certain markers useful in informing treatment of one or more subjects with one or more activin inhibitors. In certain aspects the one or more subjects can have cancer. In certain aspects the markers can include INHBA and ACVR2B. In certain aspects one or more subjects can be treated with an activin inhibitor.
Abstract translation: 本文描述了用于确定某些标记物的存在或不存在的方法和测定法，所述标记物可用于通知用一种或多种激活素抑制剂治疗一种或多种受试者。 在某些方面，一个或多个受试者可能患有癌症。 在某些方面，标记可以包括INHBA和ACVR2B。 在某些方面，可以用激活素抑制剂治疗一个或多个受试者。
-
公开(公告)号：US11541070B2
公开(公告)日：2023-01-03
申请号：US16714407
申请日：2019-12-13
Applicant: AMGEN INC. , Santa Maria Biotherapeutics, Inc.
Inventor： Huiquan Han , Christopher Michael Haqq , Isaac Ciechanover , Xiaolan Zhou , John Zhao-Nian Lu
IPC: A61K38/17 , A61K31/704 , A61K45/06 , A61K31/7068 , C07K16/22 , A61K39/395 , A61K39/00
Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
-
公开(公告)号：US20170202909A1
公开(公告)日：2017-07-20
申请号：US15316767
申请日：2015-06-15
Applicant: Santa Maria Biotherapeutics, Inc. , Amgen Inc.
Inventor： Christopher Michael Haqq , Ramil Latypov
CPC classification number: A61K38/179 , C07K14/71
Abstract: Disclosed herein is an activin receptor IIB-based composition and related methods of use, e.g., to treat solid tumors. Also disclosed are methods of manufacturing the compound and formulation.
-
-
-
-
-
Search Results
6
records
(took 0.051 seconds)
